| answer text |
<p>Public Health England (PHE) publishes weekly COVID-19 vaccine surveillance reports
which include the latest evidence on vaccine effectiveness against different outcomes.
The following table shows the latest summary of evidence on vaccine effectiveness
against different outcomes, including transmission, for Pfizer/BioNTech and University
of Oxford/AstraZeneca as of 1 July.</p><p> </p><table><tbody><tr><td rowspan="3"><p>Outcome</p></td><td
colspan="4"><p>Vaccine Effectiveness</p></td></tr><tr><td colspan="2"><p>Pfizer/BioNTech</p></td><td
colspan="2"><p>Oxford/AstraZeneca</p></td></tr><tr><td><p>1 dose</p></td><td><p>2
doses</p></td><td><p>1 dose</p></td><td><p>2 doses</p></td></tr><tr><td><p>Symptomatic
disease</p></td><td><p>55-70%*</p></td><td><p>85-95%*</p></td><td><p>55-70%*</p></td><td><p>70-85%**</p></td></tr><tr><td><p>Hospitalisation</p></td><td><p>75-85%*</p></td><td><p>90-99%**</p></td><td><p>75-85%*</p></td><td><p>80-99%***</p></td></tr><tr><td><p>Mortality</p></td><td><p>70-80%**</p></td><td><p>95-99%**</p></td><td><p>75-85%**</p></td><td><p>75-99%***</p></td></tr><tr><td><p>Infection</p></td><td><p>55-70%**</p></td><td><p>70-90%***</p></td><td><p>60-70%***</p></td><td><p>No
data</p></td></tr><tr><td><p>Transmission (secondary cases)^</p></td><td><p>45-50%***</p></td><td><p>No
data</p></td><td><p>35-50%***</p></td><td><p>No data</p></td></tr></tbody></table><p>Source:
Table 3 <a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fcovid-19-vaccine-surveillance-report&data=04%7C01%7Ccovid19surv%40phe.gov.uk%7Cb2598e32058644d021bf08d916c0fea2%7Cee4e14994a354b2ead475f3cf9de8666%7C0%7C0%7C637565840415583246%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=MFmH8qQxqsBUGSNXnO5e7tyCyPWBtYpuq%2FF3GUfu6AI%3D&reserved=0"
target="_blank">https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report</a></p><p>
</p><p> </p><p>Notes:</p><ol><li>*High Confidence - Evidence from multiple studies
which is consistent and comprehensive</li><li>**Medium Confidence - Evidence is emerging
from a limited number of studies or with a moderately level of uncertainty</li><li>***Low
Confidence - Little evidence is available at present and results are inconclusive</li><li>^effectiveness
in reducing symptomatic secondary cases in households of a symptomatic index case</li></ol><p>
</p><p>PHE plans to publish vaccine effectiveness data for Moderna when more evidence
becomes available.</p>
|
|
